Synairgen plc SYGGF
0.00 USD 0.00 (+0.00%)
At closeNov 3, 2026, 4:00 PM EST
0.0141 Day range 0.0141
0.00001 52-week range 0.0141
- YTD
- +900.00%
- 1 year
- -50.00%
News
proactiveinvestors.co.uk Synairgen shares stay tradeable post-delisting, as top investor waives restrictions Synairgen PLC (AIM:SNG, OTC:SYGGF), a biotech company developing an experimental inhaled treatment for respiratory infections, says its shares will remain freely tradeable - even after its recent…
proactiveinvestors.co.uk Synairgen becomes the latest company to eye the AIM exit door Synairgen PLC (AIM:SNG, OTC:SYGGF) is set to become the latest in a growing wave of smaller companies leaving London's AIM market after struggling to lock down fresh investment. The biotech firm,…
proactiveinvestors.co.uk Synairgen CEO on funding phase 2 trial for SNG001 - ICYMI Synairgen PLC (AIM:SNG, OTC:SYGGF) chief executive Richard Marsden talked with Proactive about the company's recent fundraising efforts to support a phase II clinical trial. The study aims to test…
proactiveinvestors.co.uk Synairgen backer ready to pump £18-£19 million into phase II trial Synairgen PLC (AIM:SNG, OTC:SYGGF), the respiratory-focused biopharmaceutical company, has announced plans to raise up to £25 million to fund the development of SNG001, its investigational inhaled…
proactiveinvestors.co.uk Synairgen making substantial progress towards phase II trial Synairgen PLC (AIM:SNG, OTC:SYGGF) said it has made 'substantial progress' preparing for a phase II trial of its lead asset, SNG001, which is being developed to treat high-risk patients with severe…
proactiveinvestors.co.uk Synairgen appoints inhaled drug development expert as chairman Synairgen PLC (AIM:SNG, OTC:SYGGF) chairman Simon Shaw will retire at next month's annual shareholder meeting, to be replaced by Mark Parry-Billings, who he called "a world class inhaled drug…
proactiveinvestors.co.uk Synairgen making plans for phase II trial Synairgen PLC (AIM:SNG, OTC:SYGGF) said it is on the "verge of embarking" on a phase II trial of SNG001, for severe viral lung infection. The focus will be on patients who are mechanically ventilated.
proactiveinvestors.com Synairgen appoints new CFO as incumbent bows out after nearly 20 years Synairgen PLC (AIM:SNG, OTC:SYGGF) said Joseph Colliver will succeed John Ward as chief financial officer effective November 6. Colliver comes to Synairgen with experience in senior finance and…
proactiveinvestors.com Synairgen hires full-time chief medical officer as drug development ramps up Synairgen PLC (AIM:SNG, OTC:SYGGF) has appointed seasoned pharmaceutical physician and drug developer Dr. Marcin Mankowski as chief medical officer, effective immediately.